BioSpace News Archive

Achieved Third Quarter 2019 ONPATTRO® Global Net Product Revenues of $46.1 Million, Including Initial Sales in Japan, with Over 600 Patients on Commercial Product Worldwide

Hemostemix Inc. is a biotechnology company developing and commercializing blood-derived stem cell therapies for unmet medical conditions, announces that it has conducted a comprehensive assessment of the status, timeline and financial requirements for the Company to complete its current ACP-01 Phase II clinical study for critical limb ischemia (“CLI”).

Predictive Oncology announces the availability of a broadcast titled, “Delivering Precision Medicine’s True Potential: Big Data, Artificial Intelligence Identify New Cancer Therapeutics.”

ANI Pharmaceuticals, Inc. announced that its partner Pharmaceutics International Inc. has received FDA approval of a Prior Approval Supplement for Bretylium Tosylate Injection, USP 500mg/10ml ANI plans to launch this currently unavailable drug in December, introducing this critical drug for the treatment of ventricular fibrillation and life-threatening ventricular arrhythmias, such as ventricular tachycardia.

Arena Pharmaceuticals, Inc. will release its third quarter 2019 financial results and provide a corporate update on Thursday, November 7, 2019, after the close of the U.S. financial markets.

In the DOVE study, fluconazole was the predominant rescue therapy when patients in the fluconazole arm failed therapy, underscoring the need for new VVC therapeutic options

Catalent Biologics today announced a long-term strategic agreement for the development and manufacturing of Zolgensma® (onasemnogene abeparvovec-xioi), an AveXis gene therapy treatment for spinal muscular atrophy (SMA).

Sientra, Inc., a medical aesthetics company, announced that its management team will participate in the following upcoming investor conferences

PTC Therapeutics, Inc. announced that on October 25, 2019 it approved non-statutory stock options to purchase an aggregate of 339,875 shares of its common stock to 27 new employees.

The company is initiating investor calls accompanying its quarterly results.